home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

'Lifeline' For Tumour Cells Can Be Cut

  March, 20 2008 8:36
your information resource in human molecular genetics

Researchers studying cancers in mice have identified a protein that is crucial for tumour survival, raising the prospect that new cancer therapies might halt tumours in their tracks by targeting this molecule.

The protein - an enzyme called endothelial nitric oxide synthase (eNOS) - is part of a complex interplay of interacting proteins that initiate and maintain the growth of tumour cells, report Christopher Counter and colleagues in Nature. Although the initiation of tumours involves a host of different proteins activated by the well known cancer gene Ras, tumour maintenance requires the portion of the Ras pathway involving eNOS.

Blocking the activation of eNOS inhibits the formation and maintenance of cancers in mice, the researchers show. Thus, targeting this process, as well as inhibiting Ras, could offer a successful strategy for new drugs to tackle cancer, they suggest.

Author contact:

Christopher Counter (Duke University Medical Centre, Durham, NC, USA)
E-mail: count004@mc.duke.edu

Abstract available online.

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.